"I am making a prediction that this drug will be released by Gilead in 2017/2018. "
Provided that GS9620 shows the expected efficacy on hbvers (and hcvers).
They've already done small cohort human trials, and the drug works and is well tolerated.
Really? They already have a small amount of data on hbvers (human), not just healthy volunteers? Were they cured? If so, that would be truly exciting.
i do hope myrcludex and replicor are able to fasten this process or imiquimod itself show some effect, this is the only thing to make them move very fast
Now, we have three horses running in the course: rep9ac(replicor), mycrludex and GS9620 ..
Good ,, i hope number of horses will increase ..
at least one of them reach to the finalist soooon ..
Actually there are 4, if you include the sRNAi from Arrowhead Research.
Had appt with Gish - he said there is unreleased data from clinical trials showing GS 9620 has been effective, and non-toxic in escalating doses. He also said clinical trials are still ongoing and they've relaxed the inclusion criteria, so others may be able to join (veteranB).